IM

Immuneering CorpNASDAQ IMRX Stock Report

Last reporting period 31 Dec, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.087

Micro

Exchange

XNAS - Nasdaq

IMRX Stock Analysis

IM

Uncovered

Immuneering Corp is uncovered by Eyestock quantitative analysis.

Market cap $B

0.087

Dividend yield

Shares outstanding

26.405 B

Immuneering Corporation is a biopharmaceutical company. The Company is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The Company's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The Company's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

View Section: Eyestock Rating